Low-Dose Naltrexone (LDN) for Long COVID: How It Works and What to Track

The old drug being used a new way

Naltrexone is not new or exotic. At 50 mg it has been used for decades to treat opioid and alcohol use disorder, where it works by blocking the opioid receptors that those substances act on. Low-dose naltrexone, almost always shortened to LDN, is the same molecule given at roughly a tenth of that dose, usually somewhere between 0.5 and 4.5 mg, for an entirely different job: quieting the low-grade neuroinflammation that appears to sit underneath long COVID, ME/CFS, and fibromyalgia.

That is the whole intrigue of LDN. It is cheap, it is generic, it has a long safety record at much higher doses, and at a tiny dose it seems to do something almost unrelated to its original use. If you spend time in long COVID or ME/CFS communities, you have seen it mentioned constantly, often with more heat than clarity. This piece is the calm version: how it is thought to work, what the evidence honestly shows, what the side effects are, and what to watch if it ends up in your plan.

These are educational field notes, not medical advice, and nothing here is a reason to start or change a medication on your own. LDN is prescription-only, it is compounded by a pharmacy rather than sold off the shelf at these doses, and every dose decision belongs with your clinician.

What is low-dose naltrexone?

The dose is the entire story. At the standard 50 mg dose, naltrexone keeps opioid receptors blocked around the clock. At a low dose, that block is brief and partial: the drug occupies the receptors for a few hours and then clears. Those two situations produce very different biology, which is why “low-dose” is doing so much work in the name.

Because no manufacturer makes a 1.5 mg or 4.5 mg tablet, LDN is prepared by a compounding pharmacy from a prescription, often as a capsule or a liquid so the dose can be nudged up slowly. That is normal and legitimate, but it is worth knowing so a compounded prescription does not come as a surprise.

How does LDN work for long COVID?

There are two leading mechanisms, and they are complementary rather than competing.

The endorphin rebound. When a low dose briefly blocks opioid receptors, the nervous system reads that as a shortage and responds by making more of its own opioids, the endorphins and enkephalins. Those molecules are not only about pain and mood; some, such as met-enkephalin, also influence immune cells. The idea is that a brief nightly nudge trains the system to run with a bit more of its own endorphin signaling, which may help rebalance an immune response that has been stuck in an activated state.

Glial calming through TLR4. This is the mechanism that has drawn the most research interest for chronic pain and post-viral illness. The nervous system has its own immune cells, the glia (microglia and astrocytes). When they are chronically activated, they pour out inflammatory signals that amplify pain and fatigue and keep the whole system on edge. Naltrexone appears to block a receptor on these cells called TLR4 (Toll-like receptor 4), which dials down that inflammatory output. In long COVID, ME/CFS, and fibromyalgia, this kind of low-grade neuroinflammation is one of the leading suspected drivers of the core symptoms: fatigue, brain fog, pain, poor sleep, and a jittery autonomic nervous system.

Notice what LDN is not. It is not an antiviral, so it is not aimed at any leftover virus. It does not restore blood volume or reverse deconditioning. Its target is the inflammatory, sensitized state of the nervous system, which is exactly why its effects are gradual and why the readouts that matter are symptoms and trends rather than a single lab value.

Does LDN actually help long COVID?

Here is where honesty matters more than enthusiasm. The evidence is real but uneven, and it is strongest in a condition next door to long COVID rather than in long COVID itself.

The clearest data are in fibromyalgia, a chronic pain condition with a lot of overlapping biology. Small randomized, placebo-controlled trials from researchers at Stanford (Younger and colleagues) found that LDN reduced pain compared with placebo. These were small studies, but they were properly controlled, which is why fibromyalgia is often cited as the proof of concept.

In ME/CFS and long COVID, the published evidence is younger and weaker: mostly uncontrolled case series, retrospective chart reviews, and patient surveys. Several report meaningful improvements in fatigue, pain, and cognitive symptoms in a subset of people, which is genuinely encouraging, but uncontrolled reports cannot separate a real drug effect from natural recovery, hope, or the ordinary ups and downs of these illnesses. Randomized controlled trials of LDN for long COVID are underway, and those are the studies that will actually settle whether, and for whom, it helps.

How is LDN taken, and how long does it take?

Two features define the practical experience of LDN: it is started low and raised slowly, and it works gradually.

Most clinicians begin at a very low dose, often around 0.5 to 1.5 mg, and increase over several weeks toward a target that commonly lands between 3 and 4.5 mg, though plenty of people do well below that. It is usually taken once a day. Timing is worth a mention: because vivid dreams are the most common early side effect, some people who take it at bedtime and sleep poorly switch to a morning dose, and it works either way.

The benefit, if it comes, builds over weeks to a couple of months, not days. That slow arc is exactly why a tracking habit is so useful here. A gradual change is easy to miss and easy to credit to the wrong thing, and memory is a poor instrument over eight weeks. A steady record turns “I think maybe I am a bit better” into something you can actually see.

What are the side effects and cautions?

LDN is generally well tolerated, which is a big part of why it gets trialed at all. The effects worth knowing:

• Vivid dreams or disrupted sleep. The most common early complaint. It often settles within a week or two, and switching from a bedtime to a morning dose usually helps.
• Headache or mild stomach upset in the first days, usually transient.
• A temporary bump in symptoms for some people as the dose is titrated, which is one reason clinicians start so low.

Then there is the one firm rule that is not optional. Naltrexone blocks opioids, so LDN cannot be combined with opioid pain medication. If you take opioids, or expect surgery or a procedure that will use them, that has to be planned around with your clinician, because naltrexone can either trigger withdrawal or leave you without pain relief when you genuinely need it. Beyond opioids, LDN is thought to have relatively few interactions, but your prescriber and pharmacist are the ones who screen your full list and set the plan.

How LDN fits with pacing and the rest of recovery

It helps to be clear about what LDN is and is not in a recovery plan. If it works, it may lower the background inflammation and sensitization that make everything harder, which can widen your margins. It does not replace the structural work of recovery: pacing to stay inside your energy envelope, respecting post-exertional malaise, sleep, and the slow, patient rebuild described in the post-viral recovery guide.

Think of a medication like this as one variable in a system with several. That framing also protects you from a common trap: crediting or blaming LDN for a change that a bad week of overexertion or a great week of rest actually caused. The way to tell them apart is to keep the rest of your inputs as steady as you can and to watch the trend over time.

What to track if LDN is in the picture

Because LDN is slow and its effect is so individual, tracking is not a nice extra here, it is how you find out whether it is working for you specifically. A few things are worth watching:

None of these are diagnostic, and none of them will move in a straight line. HRV in particular is noisy day to day, so the signal you are looking for is a gentle change in the trend across weeks, read against your own baseline rather than against a textbook number. Log the day your dose changes, because a titration step resets the story and you want to compare like with like on either side of it.

Frequently asked questions

What is low-dose naltrexone (LDN)? It is the opioid-blocking drug naltrexone, approved at 50 mg for addiction, given at a fraction of that (about 0.5 to 4.5 mg) and used off-label for conditions that appear to involve neuroinflammation, including long COVID, ME/CFS, and fibromyalgia. At these doses it is prepared by a compounding pharmacy.

How does LDN work for long COVID? The two leading theories are a brief opioid-receptor block that prompts a rebound rise in your own endorphins, and a calming of activated glial cells in the nervous system by blocking a receptor called TLR4, which lowers inflammatory signaling. It targets the sensitized, inflamed state of the nervous system, not a virus.

Does LDN actually help long COVID? It might, for some people, but the evidence is early. It is strongest in fibromyalgia (small randomized trials), and in long COVID and ME/CFS the reports are mostly uncontrolled, with randomized trials underway. It is low-risk and well tolerated, which is why it gets trialed, but it is not a proven cure.

What are the side effects of LDN? Usually mild: vivid dreams or disrupted sleep early on (often helped by changing the dose timing), sometimes headache or stomach upset. The key caution is that it cannot be combined with opioid pain medication and must be paused before opioid-based surgery.

How long does LDN take to work? Slowly. It is titrated up over weeks, and any benefit tends to build over one to three months rather than days, which is exactly why a steady tracking habit helps you see it.

Can I take LDN with my other medications? Ask your prescriber and pharmacist. The firm rule is no opioids with naltrexone. Otherwise it is thought to have relatively few interactions, but your clinician screens your list and sets the dose.

The bottom line

Low-dose naltrexone is an old, cheap drug used in a genuinely clever way: a tiny dose of an opioid blocker aimed not at addiction but at the low-grade neuroinflammation that may sit underneath long COVID, ME/CFS, and fibromyalgia. The mechanism, a brief opioid-receptor block that raises your own endorphins plus a calming of the nervous system’s glial cells through TLR4, is plausible and interesting. The evidence is strongest in fibromyalgia and still early in long COVID, so it is best treated as a reasonable, well-tolerated experiment run with a clinician rather than a proven cure. It works slowly, it does not mix with opioids, and it does not replace pacing, sleep, and the rest of recovery. Because the change is gradual and so individual, the honest way to know if it is helping is to track your symptoms, resting heart rate, and HRV against your own baseline, and to give the trend enough weeks to speak.